



PHACILITATE:

TRADE MISSION NAVIGATING ASIA

26-28 JUNE 2018

Tuesday 26th June InterContinental Grand Seoul Parnas

Tuesday 26th June

8.30 Registration and breakfast

The strategic Korean advanced therapeutics landscape; why should the West collaborate with Korean partners?

9.00 Welcome note

Byung-Seon Jeong, *Assistant Minister Office of R&D Policy, Ministry of Science & ICT*

Gang-rip Kim, *Deputy Minister, Office of Planning and Coordination, Ministry of Health and Welfare*

B. G. Rhee, *CEO, SCM Life Science; Chairman, Council for Advanced Regenerative Medicine (CARM)*

Dong-Yeon Kim, *Chairman of the board, Korea Drug Research Association*

9.15 Growing the Pie through "i to i"; Investigators to Investors

William D. Milligan, *VP Business Development, AventaCell BioMedical Corp., Ltd.; Co-Chair, ISCT Business Models and Investor Committee, ISCT Commercialization committee*

9.30 Strategic attractiveness of Korea to the west: why Korea?

- Korean advanced therapy landscape
- Market attractiveness and accessibility
- Preclinical & Clinical Development Infrastructure
- Reimbursement

Sora Park, *Professor, MD, Inha University School of Medicine; Director, GSRAC*

9.45 The Korean government R&D investment

Ho-Joon Lee, *Deputy Director, Bioscience Technology Department Office of R&D Policy, Ministry of Science & ICT*

10.00 The Korean regulatory environment: understanding the regulations at a practical level

Kyung-tak Nam, *Senior Scientific Officer, Biopharmaceuticals Management Division, Biopharmaceuticals and Herbal Medicine Evaluation Department, Ministry of Food and Drug Safety National Institute of Food and Drug Safety Evaluation*

10.20 Everything you need to know about establishing business partnerships in Korea

- The who's who
- Business landscape: who should the west be building relationships with in the Korean advanced therapies sector to establish successful partnerships
- Where can the western companies build value in Korea to aid faster product approvals?

David Kim, *CEO, MaSTherCell Korea & Cure Therapeutics Inc.*

10.40 Morning Coffee and networking

Striving towards commercialisation of advanced therapies in Korea; insights into what has been successful in the west

Chair: Hunché Cho, *Director, Korea Drug Research Association*

11.00 The Business of Regenerative Medicine: State of the Financial Markets

Dr Reni Benjamin, *Managing Director, Biotechnology Equity Research, Raymond James & Associates, Inc*

11.15 Presentation

Dr Anthony Davies, *President, Dark Horse Consulting*

11.30 Case study- Western Biotech: overcoming the challenges in managing the commercialisation of an advanced therapy product

- How can we adopt these learning's and apply to the Korean advanced therapies market?
- What does the business model look like?

KITE / Novartis

Partnering Opportunities

11.45 Korean biotech showcase

Seungshin Yu, Ph.D., *Executive Director, Strategic Business Development, ViroMed Co., Ltd.*

12.00 Western biotech showcase

Dr Stefanos Theoharis, *SVP Corporate Development & Partnering, Cell Medica*

12.15 Korean biotech showcase

Antonio Lee, Ph.D., *Global Head, Business Development, MEDIPOST Co., Ltd.*

What does a successful vein to vein business model look like in the west; logistics, tracking, traceability and manufacturing under the microscope

12.30 Presentation- Raw material use in the West

Anette Thiessen, *Key Account Manager, CellGenix GmbH*

12.45 *Presentation reserved*

1.00 *Close of content and networking lunch*

2.00 *3.5 hours of 121 partnering meetings - Pre-scheduled on the Phacilitate networking tool*

5.00 *Networking drinks*

7.30 *Partnering dinner at Phylkyungjae*